Molecular subtypes and response to immunotherapy in bladder cancer patients

The introduction of immunotherapy for the treatment of patients with advanced urothelial carcinoma has led to a significant interest in markers predicting therapy response. As in other tumor entities, approximately 20% of patients show objective response to single drug checkpoint inhibition. The identification of these patients is of great interest in order to avoid ineffective and expensive treatment.